In the long-run we are all dead: on the benefits of peer punishment in rich environments

Dirk Engelmann,N. Nikiforakis

DOI: https://doi.org/10.1007/s00355-015-0884-5

2015-03-07

Social Choice and Welfare

Abstract:

What problem does this paper attempt to address?

Effects of Gonadotropin-Releasing Hormone Antagonists on the Expression of Vascular Endothelial Growth Factor and Its Receptors in a Rat Model of Ovarian Hyperstimulation Syndrome.

Tong Xiao-mei,Zhang Song-ying,Song Tao,Xu Wei-hai,Lin Xiao-na,Shu Jing,Liu

DOI: https://doi.org/10.1097/00029330-200812010-00014

2008-01-01

Abstract:BACKGROUND:Ovarian hyperstimulation syndrome (OHSS) is one of the most life-threatening complications of assisted reproduction treatments. Gonadotropin-releasing hormone antagonists (GnRHanta) are thought to be effective in preventing this complication, and some clinical trials have found lower incidences of OHSS in patients treated with GnRHanta. Our aim was to investigate the effects of GnRHanta on vascular permeability and the expression of vascular endothelial growth factor (VEGF) and its receptors in a rat model of OHSS.METHODS:An immature early OHSS rat model was established. Three ovarian stimulation protocols were used: pregnant mare serum gonadotropin/human chorionic gonadotropin (hCG) alone, with a GnRHanta, or with a gonadotropin-releasing hormone agonists (GnRHa). Blood and tissue samples were collected at 48 hours after hCG administration. Vascular permeability was evaluated by measuring the Evans-Blue content of extravasated peritoneal fluids. The expression of VEGF and its receptors, including flt-1 and KDR, were detected by reverse transcriptase-polymerase chain reaction and Western blotting.RESULTS:Treatment with both a GnRHanta and a GnRHa resulted in significant reductions in serum estradiol and peritoneal vascular permeability, as well as decreased ovarian expression of VEGF and its two receptors. However, GnRHanta treatment caused a greater reduction in serum estradiol concentrations, and in VEGF receptor mRNA expression than GnRHa. There were no significant reductions in the expression of VEGF or its receptors in extra-ovarian tissues, including the liver, lungs and peritoneum.CONCLUSION:Our results reveal that GnRHanta are more potent than GnRHa in preventing early OHSS through down-regulation of the expression of VEGF and its receptors in hyperstimulated ovaries.
Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas

Andrea Di Lieto,Marianna De Falco,Fabrizio Pollio,Gelsomina Mansueto,Gaetano Salvatore,Pasquale Somma,Francesca Ciociola,Gaetano De Rosa,Stefania Staibano

DOI: https://doi.org/10.1016/j.jsgi.2004.10.008

Abstract:Objective: Basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) are involved in the pathogenesis of leiomyomas and influence angiogenesis, which is necessary for growth of leiomyomas. Gonadotropin-releasing hormone analogue (GnRH-a) treatment might modify the growth factor expression and the blood supply in myomas. We investigated the effects of GnRH-a treatment on some clinical parameters, on the immunohistochemical expression of bFGF, VEGF, and PDGF, and on the vasculature of leiomyomas. Methods: Thirty-one women were treated with leuprolide acetate for 3 months; 55 untreated patients formed the control group. Hematologic parameters were assessed at the admission, after GnRH-a treatment, and after surgery. Uterine volume was evaluated by ultrasonography. The immunoexpression of bFGF, VEGF, and PDGF and of the endothelial markers CD34 and CD105, as well as the vascular pattern, were studied in leiomyomas, comparing treated and untreated patients. Results: Hematologic parameters improved and uterine volumes decreased after GnRH-a treatment. The immunoexpression of bFGF, VEGF, and PDGF decreased in treated myomas, together with the total number of vessels and the angiogenetic vessels. Conclusion: This study confirms the clinical response of uterine shrinkage after GnRH-a treatment. A pathogenetic role of bFGF, VEGF, and PDGF in myoma growth and vascularization is suggested. Finally, this study indirectly confirms the importance of the vasculature in leiomyoma growth.
The hemodynamic effect of GnRH agonist therapy on uterine leiomyoma vascularity: a prospective study using transvaginal color Doppler sonography

F A Aleem,M Predanic

DOI: https://doi.org/10.3109/09513599509160454

Abstract:The objective of this study was to correlate, during 12 weeks of therapy with gonadotropin releasing hormone agonist (GnRH-a), the chronological effect and the hemodynamic changes on the uterine artery and the leiomyometrial supplying vessels. Twenty-three premenopausal women with clinically diagnosed uterine leiomyomas received 3.75 mg of leuprolide acetate intramuscularly every 4 weeks for 12 weeks. Pretreatment values of serum estradiol, uterine and leiomyoma volumes and blood flow characteristics of the main uterine artery and leiomyoma supplying vessels-resistance index (RI), pulsatility index (PI) and peak-systolic velocity, obtained by transvaginal color Doppler sonography-were compared with treatment values at 4, 8 and 12 weeks of leuprolide acetate therapy. The first event in the chronological response to the GnRH-a therapy was a statistically significant increase in RI and PI values for major leiomyoma vessels, observed at the end of the 4th week (p < 0.05), which increased significantly after 8 and 12 weeks (p < 0.01 and p < 0.001, respectively). These findings were in direct correlation with a significant decrease of estradiol levels after 4, 8 and 12 weeks (p < 0.05, p < 0.001 and p < 0.001, respectively). The significant decrease of blood flow in the leiomyometrial vessels was followed by a significant decrease of the main uterine artery blood flow after 8 weeks and uterine and leiomyoma volumes by 42% and 55%, respectively, after 12 weeks of GnRH-a therapy. We concluded that a significant increase in leiomyometrial vessels RI and PI values, which was found 4 weeks after the first dose of GnRH-a, but without major leiomyoma volume decrease, emphasizes that the first significant effect of GnRH therapy in the process of uterine and leiomyoma volume shrinkage is the reduction of leiomyometrial rather than uterine blood flow. This effect is followed by a considerable reduction of uterine vascularity and a significant decrease of uterine and leiomyoma volumes. If a decrease of blood loss during myomectomy is the main aim of GnRH-a therapy, we believe that 8 weeks would be an appropriate therapy duration.
Effects of gonadotropin-releasing hormone agonists on uterine volume and vasculature and on the immunohistochemical expression of basic fibroblast growth factor (bFGF) in uterine leiomyomas

A Di Lieto,M De Falco,S Staibano,F Iannotti,M Scaramellino,G Salvatore,G Mansueto,P Granata,M Pontillo,F Pollio,G De Rosa

DOI: https://doi.org/10.1097/01.PGP.0000070849.25718.73

Abstract:We investigated the effect of the GnRH agonist (GnRH-a) on the uterine volume and on the immunohistochemical expression of basic fibroblast growth factor (bFGF) and the vasculature of leiomyomas. Twenty-five women were treated with leuprorelin acetate for 3 months; 46 untreated patients were enrolled as a control group. The uterine volume was measured by ultrasonography. After myomectomy or hysterectomy, the immunoexpression of bFGF and the endothelial marker, CD34, was studied and compared in treated and untreated leiomyomas. Uterine volume decreased after therapy. The number of cells expressing bFGF and the vascularity were diminished in treated leiomyomas. Reduction in the blood supply might be responsible, in part, for uterine-volume shrinkage after GnRH-a therapy.
The role of VEGF and TGF-β blood levels for fibroid shrinkage, menorrhagia score, and quality of life improvement after uterine artery embolization for uterine fibroids: a study protocol

Gulzhanat Aimagambetova,Gauri Bapayeva,Talshyn Ukybassova,Viktor Zemlyanskiy,Arnur Gusmanov,Milan Terzic

DOI: https://doi.org/10.3389/fmed.2024.1382822

IF: 3.9

2024-08-06

Frontiers in Medicine

Abstract:Uterine leiomyoma is a common condition affecting women that occurs in more than 70% of females. Women with leiomyomas overall have lower quality of life and deficiency in many specific spheres of life including work-related productivity, sexuality, relationships, social–emotional health, and physical well-being that might be present even in pre-and extended throughout early postmenopausal life. Choices for symptomatic fibroid management include medical, interventional radiology procedures, surgical, and expectant management. The uterine artery embolization (UAE) procedure has gained justified popularity for myoma management. Growth factors, vascular endothelial growth factor (VEGF) and tumor growth factor β (TGF-β), hold an important role in leiomyoma progression. However, blood levels of VEGF and TGF-β in patients before and after UAE are not fully investigated and the possible relationship with myoma shrinkage has not been evaluated. Therefore, this study aims to assess menorrhagia score and quality of life improvement after UAE for uterine fibroids and compare blood levels of VEGF and TGF-β in patients with uterine leiomyoma before and after UAE. This cross-sectional study will be performed at the University Medical Center, Astana, Kazakhstan. Women undergoing the UAE procedure for uterine leiomyoma will be involved in the study following the precisely defined inclusion/exclusion criteria. Uterine leiomyoma nodules’ structural changes after UAE will be assessed along with the blood levels of growth factors (VEGF and TGF-β), menorrhagia score, and quality of life. An important outcome of this project will be an investigation of the blood levels of growth factors (VEGF and TGF-β) before and after the procedure and their association with leiomyoma shrinkage in correlation with the menorrhagia score and quality of life alterations among patients undergoing UAE.

medicine, general & internal
N-Acetylcysteine enhances UV-mediated caspase-3 activation, fragmentation of E2F-4, and apoptosis in human C8161 melanoma: inhibition by ectopic Bcl-2 expression.

M. Rieber,M. Rieber

DOI: https://doi.org/10.1016/S0006-2952(03)00147-3

IF: 6.1

2003-05-15

Biochemical Pharmacology

Abstract:
Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment

F Ito,N Kawamura,T Ichimura,A Tsujimura,O Ishiko,S Ogita

DOI: https://doi.org/10.1016/s0015-0282(00)01660-5

Abstract:Objective: To compare ultrastructural features of leiomyoma cells from the same uterine myoma nodule before and after GnRH agonist (GnRH-a) treatment and to examine the relation between these ultrastructural changes and the extent of myoma volume reduction with GnRH-a treatment. Design: Prospective clinical study. Setting: University teaching hospital. Patient(s): Twenty women with uterine leiomyomas who were scheduled for surgery. Intervention(s): Transcervical needle biopsy of uterine myoma, s.c. leuprolide acetate injection (3.75 mg) at least three times every 4 weeks before surgery, and hysterectomy or myomectomy. Main outcome measure(s): The changes in ultrastructural features of uterine leiomyoma cells and the percentage decrease in the volume of the largest myoma at 12 weeks of GnRH-a treatment measured by magnetic resonance imaging. Result(s): A decrease in myofilaments, mitochondrial swelling, and emergence of the lysosomal body were observed in relation to GnRH-a treatment. Furthermore, a positive correlation was observed between the decrease in myofilaments and myoma shrinkage. Conclusion(s): Cellular atrophy due to a decrease in myofilaments plays a major role in the reversible myoma shrinkage resulting from GnRH-a treatment.
Prediction of the shrinking rate of uterine leiomyoma nodules using needle biopsy specimens

Mari Kasai,Tomoyuki Ichimura,Naoki Kawamura,Tomoko Sumikura,Makiko Matsuda,Chika Asano,Toshiyuki Sumi,Osamu Ishiko

DOI: https://doi.org/10.1016/j.fertnstert.2012.05.013

Abstract:Objective: To determine correlations between shrinkage of uterine leiomyomas after treatment with GnRH agonists (GnRH-a) or menopause and expression levels of estrogen receptors (ER), progesterone receptors (PR), and vascular endothelial growth factor (VEGF). Design: Cohort study. Setting: University teaching hospital. Patient(s): A total of 26 women with uterine leiomyoma. Intervention(s): Ten women were treated with buserelin acetate injection (1.8 mg), four courses every 4 weeks, and 16 women went into menopause naturally. Main outcome measure(s): Tumor shrinkage rates determined from magnetic resonance images taken before and after GnRH-a therapy and before and after natural menopause; immunohistochemical analysis of ER, PR, and VEGF in uterine leiomyoma biopsy specimens taken before intervention or within 6 months before menopause. Result(s): Shrinkage rates of uterine leiomyomas were positively correlated with expression levels of ER in women treated with GnRH-a and in postmenopausal women managed conservatively, and with VEGF expression in women treated with GnRH-a. There were no significant correlations with PR expression levels in either group. Conclusion(s): Estrogen plays the predominant role in myoma shrinkage for women with GnRH-a therapy and naturally menopausal women.
Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor

Marianna De Falco,Stefania Staibano,Francesco Paolo D'Armiento,Massimo Mascolo,Gaetano Salvatore,Anna Busiello,Ilma Floriana Carbone,Fabrizio Pollio,Andrea Di Lieto

DOI: https://doi.org/10.1016/j.jsgi.2006.02.008

Abstract:Objective: To evaluate the clinical features and the expression of transforming growth factor-beta3 (TGF-beta3) and connective tissue growth factor (CTGF) in myometrium and uterine leiomyomas after preoperative treatment with gonadotropin-releasing hormone-analogs (GnRH-a) and tibolone. Methods: Twenty-three patients received 3.75 mg leuprolide acetate depot for 4 months. Twenty-two patients received the same therapy plus 2.5 mg tibolone daily. Patients underwent uterine surgery after therapy. Twenty-two untreated patients underwent surgery directly. Hematologic tests, bone mineral density (BMD) measurement, and ultrasonographic evaluation of uterine volume were performed before and after treatment. Menorrhagia and pelvic pain were evaluated with a visual analog scale. Hot flushes were recorded in daily diaries. Immunohistochemical expression of TGF-beta3 and CTGF in myometrium and myoma samples was evaluated semiquantitatively. Results: After therapy, hemoglobin and iron levels similarly increased in both groups. BMD significantly decreased only in the GnRH-a group. Uterine volume similarly decreased in both groups. No patient had menorrhagia or pelvic pain at the end of therapy. The number of hot flushes increased after the first month in the GnRH-a group; in the GnRH-a plus tibolone group, it remained constant and was lower. In untreated cases, TGF-beta3 and CTGF smooth muscle cell immunoexpression was lower in myometrium than in leiomyomas. After medical treatment, growth factor immunoexpression remained unchanged in myometrial samples and was reduced in leiomyomas. Endothelial cells showed strong immunopositivity, both in untreated and in treated cases. Conclusion: This study focuses on the effects of GnRH-a and tibolone on TGF-beta3 and CTGF expression in myometrium and myomas and supports the hypothesis of a pathogenetic role of these growth factors in uterine fibromatosis.
Involvement of parathyroid hormone-related peptide in cell proliferation activity of human uterine leiomyomas

M Yoshida,A Ohtsuru,T Samejima,M Okazaki,A Fujishita,M Ito,S Yamashita,T Ishimaru

DOI: https://doi.org/10.1507/endocrj.46.81

Abstract:Uterine leiomyomas develop from uterine smooth muscle cells, which are known to be regulated by estrogen and other growth factors. The purpose of this study was to investigate the role of expression of parathyroid hormone related-peptide (PTHrP) in the growth of uterine leiomyomas treated or untreated with gonadotropin-releasing hormone agonist (GnRH-a). Thirty-nine leiomyoma tissues were obtained from 36 patients who had been treated with GnRH-a (n=10) or without GnRH-a (n=29). The intensity of PTHrP immunostaining was categorized into three grades; "negative", "weakly positive", and "positive". Leiomyoma cell growth was estimated by the proliferating cell nuclear antigen (PCNA) labeling index (LI) with an image analyser. We also investigated the correlation between PTHrP expression and cell proliferation or histopathological findings. In the GnRH-a-untreated group, LI of the PTHrP "positive" group was significantly higher than that of the PTHrP "negative" group, but the intensity of PTHrP immunostaining did not correlate with LI in the GnRH-a-treated group. PTHrP expression did not correlate with histological findings or clinical parameters (age and phase of menstrual cycle) in either the GnRH-a-treated or the -untreated group. In addition, the expression of mRNA for PTHrP and its receptor was detected in leiomyomas by reverse transcriptase-polymerase chain reaction (RT-PCR). Our results indicate that the expression of PTHrP in leiomyomas correlated positively with cell growth in the GnRH-a-untreated group, suggesting that PTHrP may act as a local cell growth modifier in an autocrine/paracrine fashion on uterine leiomyomas.
Clinical Significance of Serum VEGF, IGF-1 and CA125 Levels in the Uterine Artery Embolization Treatment for Uterine Adenomyosis

Bin WAN,Ke HAN,Zeng-rong LIU,Li-xiang ZHU,Jing CHEN

DOI: https://doi.org/10.13241/j.cnki.pmb.2017.11.015

2017-01-01

Abstract:Objective:To investigate the correlation of serum concentration of vascular endothelial growth factor (VEGF),insulin-like growth factor 1 (IGF 1) and CA125 with uterine artery embolization (UAE) in the treatment of uterine adenomyosis.Methods:39 cases of uterine adenomyosis patients were chosen as patient group and received uterine artery embolization,30 healthy subjects were selected as control.The serum concentrations ofVEGF,IGF 1,CA125 before and after the operation were quantified by ELISA at different time points.The curative effect after uterine artery embolization was evaluated.Results:After 1 month of UAE,in 34 patients with dysmenorrhea,29 cases turned to be complete remission with its final efficiency of 85.2％.The VEGF,IGF 1 and CA125 concentrations in serum of patient group were significantly higher than those of normal control group before UAE treatment (P＜0.05).After uterine artery embolization,the serum concentrations of IGF 1,VEGF and CA125 of patient group decreased significantly.After 6 months of UAE treatment,all indicators turned to be at normal level.Conclusion:The changes of serum IGF-1,VEGF and CA125 concentrations could be taken as curative effect and prognosis marker of uterine artery embolization in the treatment of uterine adenomyosis.
Cetorhinicola n. g., Shirleyrhynchus n. g. and Stragulorhynchus n. g., three new genera of trypanorhynch cestodes from elasmobranchs in Australian waters

I. Beveridge,R. A. Campbell

DOI: https://doi.org/10.1007/BF00182028

1988-07-01

Systematic Parasitology

Abstract:
Effect of pyrrolizidine alkaloids from tansy ragwort (senecio jacobaea) on hepatic drug-metabolizing enzymes in male rats.

C. Miranda,P. Cheeke,D. Buhler

DOI: https://doi.org/10.1016/0006-2952(80)90080-5

IF: 6.1

1980-10-01

Biochemical Pharmacology

Abstract:
[Non-cardiogenic pulmonary edema induced by hydrochlorothiazide].

E. Pedrol,X. Bosch,J. C. Sajche,J. Font

1989-10-01

Abstract:
Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas

Masato Nakayama,Tomoko Mitsuhashi,Yoshihiko Shimizu,Osamu Ishihara,Michio Shimizu

DOI: https://doi.org/10.1111/j.1440-1827.2008.02222.x

Abstract:Gonadotropin-releasing hormone agonist (GnRH-a) therapy is frequently applied to reduce the volume of uterine leiomyomas (UL). In addition, the possible relationship between mast cells (MC) within UL and the development of UL has been suggested, but the role of MC in UL remains to be determined. UL with or without GnRH-a therapy in 121 premenopausal patients were reviewed. The number of MC was evaluated between the two groups, immunohistochemistry was done for insulin-like growth factor-I (IGF-I), and the association between the IGF-I immunoreactivity in UL and the GnRH-a therapy was analyzed. The number of MC significantly increased in UL in GnRH-a therapy, while IGF-I immunoreactivity was significantly reduced in smooth muscle cells of these UL. Furthermore, IGF-I immunoreactivity in MC was inversely correlated with the size reduction rate of UL in GnRH-a therapy. Although GnRH-a therapy is considered to reduce the size of UL transiently, the regression of UL was in part hampered by the increased IGF-I secretion from the increased MC after GnRH-a therapy. Therefore, the more the IGF-I secretion from MC in UL increases, the less effective the GnRH-a therapy is on the size reduction of UL. Thus, the present study may provide an explanation of the possible mechanism of GnRH-a resistance in UL.
Study on the Expression of Vascular Endothelial Growth Factor in Patients with Adenomyosis of the Uterus

Yanhua Han,Yingfang Zhou,Shurong Zheng

DOI: https://doi.org/10.3760/j.issn:0529-567x.2002.09.009

2002-01-01

Abstract:OBJECTIVE:To investigate the role of angiogenesis and expression of vascular endothelial growth factor (VEGF) in the pathophysiology of adenomyosis of the uterus. METHODS:The study included 32 patients with histologically proven adenomyosis and 30 patients with asymptomatic leiomyoma of the uterus. Immunohistochemical staining was used to detect VEGF expression in different parts of the uterus. A computerized morphometric study on the VEGF expression was performed. RESULTS:The VEGF H-Score of glandular cells in the endometrium of adenomyosis uterus [proliferative phase (9.6 +/- 1.4), secretory phase (11.7 +/- 1.6)] was much higher than that of leiomyoma uterus [proliferative phase (8.3 +/- 1.7), secretory phase (10.2 +/- 1.5)] (P < 0.05), and increased in the secretory phase (P < 0.05). Compared with eutopic endometrium, the VEGF H-Score in ectopic endometrium [proliferative phase (11.9 +/- 1.8), secretory phase (13.0 +/- 1.7)] increased significantly (P < 0.05), but showed no cyclic change (P > 0.05). The VEGF H-Score of myometrium around the ectopic lesions [proliferative phase (9.5 +/- 1.3), secretory phase (8.7 +/- 1.3)] was higher than that of normal myometrium [proliferative phase (4.8 +/- 1.9), secretory phase (4.5 +/- 1.4)] (P < 0.01). CONCLUSION:The angiogenesis activity of the endometrium and myometrium of adenomyosis uterus was markedly increased.
A novel frequency planning algorithm for mitigating unfairness in wireless LANs

Yigal Bejerano,Seung-Jae Han,Mark Smith

DOI: https://doi.org/10.1016/j.comnet.2010.04.009

2010-10-01

Abstract:
Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy

Khaleque Newaz Khan,Michio Kitajima,Koichi Hiraki,Akira Fujishita,Ichiro Sekine,Tadayuki Ishimaru,Hideaki Masuzaki

DOI: https://doi.org/10.1093/humrep/dep437

Abstract:Background: Information is limited regarding the multifunctional role of GnRH agonist (GnRHa) therapy in reproductive diseases. We investigated the pattern of changes in inflammatory reaction, micro-vessel density and apoptosis in the tissues collected from women with endometriosis, adenomyosis and uterine myoma who were treated with or without GnRHa therapy. Methods: Biopsy specimens were collected from lesions, myometria and corresponding endometria of 45 women with ovarian endometrioma, 35 women with adenomyosis and 56 women with uterine myoma. A fraction of these women were treated with GnRHa therapy for a variable period of 3-6 months before surgery. We performed immunohistochemical analysis of CD68, a macrophage (Mvarphi) marker and von Willebrand factor (VWF), a vessel marker, using respective antibodies. Changes in apoptosis were examined using TdT-mediated dUTP-biotin nick end-labeling assay and by the immunoexpression of activated caspase-3 in tissues after GnRHa therapy. Results: The infiltration of CD68-positive Mvarphi and VWF-positive micro-vessel density were significantly decreased in the endometria of women with endometriosis, adenomyosis and uterine myoma in the GnRHa-treated group when compared with that in the non-treated group. Marked decreases in inflammatory and angiogenic responses were observed in lesions and myometria of these diseases. When compared with the non-treated group, a significant increase in apoptotic index (apoptotic cells per 10 mm(2) area) and quantitative-histogram scores of activated caspase-3 after GnRHa therapy were observed in the eutopic endometria, lesions and myometria of these diseases. Conclusions: GnRHa was able to markedly reduce the inflammatory reaction and angiogenesis and to significantly induce apoptosis in tissues derived from women with endometriosis, adenomyosis and uterine myoma. These multiple biological effects at the tissue level may be involved in the regression of these reproductive diseases.
Leiomyoma pseudocapsule after pre-surgical treatment with gonadotropin-releasing hormone agonists: relationship between clinical features and immunohistochemical changes

Marianna De Falco,Stefania Staibano,Massimo Mascolo,Chiara Mignogna,Luigi Improda,Francesca Ciociola,Ilma F Carbone,Andrea Di Lieto

DOI: https://doi.org/10.1016/j.ejogrb.2009.02.006

Abstract:Objective: To evaluate if pre-operative GnRH-a modify uterine leiomyoma pseudocapsule and the possible clinical effects of these changes. Study design: The study was performed at the University Federico II of Naples on 33 premenopausal patients submitted to laparotomic myomectomy after treatment with triptorelin depot. 29 untreated patients formed the control group. The operating time, the intraoperative bleeding and the prompt identification of the cleavage plan between myoma and myometrium were evaluated. The pseudocapsule features and the immunoexpression of PCNA and CD34 in this area were studied. Results: Treated patients showed lower blood loss and not clearly identifiable cleavage plan, but without any significant increase in the operating time. Treated lesions showed less evident border between myoma and myometrium and lower PCNA and CD34 pseudocapsule immunoexpression than untreated ones. Conclusion: We propose the changes of leiomyoma pseudocapsule as partial explanations of the reported clinical and surgical findings after pre-operative GnRH-a.

In the long-run we are all dead: on the benefits of peer punishment in rich environments

Effects of Gonadotropin-Releasing Hormone Antagonists on the Expression of Vascular Endothelial Growth Factor and Its Receptors in a Rat Model of Ovarian Hyperstimulation Syndrome.

Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas

The hemodynamic effect of GnRH agonist therapy on uterine leiomyoma vascularity: a prospective study using transvaginal color Doppler sonography

Effects of gonadotropin-releasing hormone agonists on uterine volume and vasculature and on the immunohistochemical expression of basic fibroblast growth factor (bFGF) in uterine leiomyomas

The role of VEGF and TGF-β blood levels for fibroid shrinkage, menorrhagia score, and quality of life improvement after uterine artery embolization for uterine fibroids: a study protocol

N-Acetylcysteine enhances UV-mediated caspase-3 activation, fragmentation of E2F-4, and apoptosis in human C8161 melanoma: inhibition by ectopic Bcl-2 expression.

Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment

Prediction of the shrinking rate of uterine leiomyoma nodules using needle biopsy specimens

Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor

Involvement of parathyroid hormone-related peptide in cell proliferation activity of human uterine leiomyomas

Clinical Significance of Serum VEGF, IGF-1 and CA125 Levels in the Uterine Artery Embolization Treatment for Uterine Adenomyosis

Cetorhinicola n. g., Shirleyrhynchus n. g. and Stragulorhynchus n. g., three new genera of trypanorhynch cestodes from elasmobranchs in Australian waters

Effect of pyrrolizidine alkaloids from tansy ragwort (senecio jacobaea) on hepatic drug-metabolizing enzymes in male rats.

[Non-cardiogenic pulmonary edema induced by hydrochlorothiazide].

Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas

Study on the Expression of Vascular Endothelial Growth Factor in Patients with Adenomyosis of the Uterus

A novel frequency planning algorithm for mitigating unfairness in wireless LANs

Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy

Leiomyoma pseudocapsule after pre-surgical treatment with gonadotropin-releasing hormone agonists: relationship between clinical features and immunohistochemical changes